Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 15/20 | 1.00 |
| ▸ | HPGD | P15428 | 12/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Jatamansin SCHEMBL29385603 | 1.00 | KDM4E (1.00) | KDM4EHPGDCYP3A4HSD17B10ALDH1A1 | |
| Jatamansin SCHEMBL12062120 | 1.00 | KDM4E (1.00) | KDM4EHPGDCYP3A4HSD17B10ALDH1A1 | |
| Jatamansin SCHEMBL14523891 | 1.00 | KDM4E (1.00) | KDM4EHPGDCYP3A4HSD17B10ALDH1A1 | |
| Jatamansin SCHEMBL30634819 | 1.00 | KDM4E (1.00) | KDM4EHPGDCYP3A4HSD17B10ALDH1A1 | |
| SCHEMBL31349688 | 0.90 | KDM4E (0.81) | KDM4EHPGDCYP3A4HSD17B10ALDH1A1 | |
| SCHEMBL29707867 | 0.86 | KDM4E (0.76) | KDM4EHPGDCYP3A4HSD17B10ALDH1A1 | |
| Decursinol Angelate SCHEMBL14310264 | 0.79 | MAOA (0.76) | KDM4EHPGDCYP3A4HSD17B10ALDH1A1 | |
| Decursinol Angelate SCHEMBL3901157 | 0.79 | MAOA (0.76) | KDM4EHPGDCYP3A4HSD17B10ALDH1A1 | |
| Decursinol Angelate SCHEMBL4740622 | 0.79 | MAOA (0.76) | KDM4EHPGDCYP3A4HSD17B10ALDH1A1 | |
| Decursinol Angelate SCHEMBL3901154 | 0.79 | MAOA (0.76) | KDM4EHPGDCYP3A4HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-02-19 | — | — | US | claimed |
| US-20250090621-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-03-20 | — | — | US | claimed |
| US-20250057805-A1 | METHODS FOR ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF BEVEMIPRETIDE | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-02-20 | — | — | US | claimed |
| US-20240299486-A1 | ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF ELAMIPRETIDE | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-09-12 | — | — | US | claimed |
| WO-2023230322-A1 | ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF ELAMIPRETIDE | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-11-30 | — | — | WO | claimed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4719404-A2 | METHODS FOR ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF BEVEMIPRETIDE | Stealth BioTherapeutics Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250302909-A1 | METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250090621-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-03-20 | — | — | US | disclosed |
| US-20250057805-A1 | METHODS FOR ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF BEVEMIPRETIDE | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-02-20 | — | — | US | disclosed |
| WO-2024254164-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024243490-A2 | METHODS FOR ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF BEVEMIPRETIDE | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20240299486-A1 | ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF ELAMIPRETIDE | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-09-12 | — | — | US | disclosed |
| WO-2023230322-A1 | ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF ELAMIPRETIDE | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | NR2E3, ALDH1A2, PDE6D | KDM4E 1988/4885HPGD 1530/4885CYP3A4 3249/4885 |
| US-20250090621-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | PDE6C, PDE6A, PDE6B | KDM4E 4401/4885HPGD 1016/4885CYP3A4 4872/4885 |
| US-20250302909-A1 | METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | PDE6C, PDE6A, PDE6B | KDM4E 4100/4885HPGD 435/4885CYP3A4 4864/4885 |
| US-20250057805-A1 | METHODS FOR ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF BEVEMIPRETIDE | MRGPRX2, MRGPRX4, MRGPRX1 | KDM4E 986/4885HPGD 898/4885CYP3A4 187/4885 |
| US-20240299486-A1 | ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF ELAMIPRETIDE | MRGPRX2, MRGPRX1, MRGPRX4 | KDM4E 1874/4885HPGD 1895/4885CYP3A4 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.